Skip to search formSkip to main contentSkip to account menu

atrasentan

Known as: (2R,3R,4S)-4-(1,3-Benzodioxo-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic Acid, 2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid, atrasentan [Chemical/Ingredient] 
A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called endothelin-1 protein receptor antagonists.
National Institutes of Health

Related topics

Related topics

7 relations

Narrower (2)

A 127722Xinlay
A 147627ABT 627atrasentan hydrochloride

Broader (2)

Endothelin receptor antagonistPyrrolidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Stabilized pharmaceutical dosage form containing the atrasentan
The present disclosure is (a) atrasentan or stabilized pharmaceutical dosage form containing the other therapeutic agent by a… 
2011
2011
Aspirin and arteriovenous graft thrombosis in hemodialysis: just what the doctor ordered?
The Center for Medicare and Medicaid Services' (CMS) Fistula First initiative has changed dialysis practice. In 2003, more than… 
2010
2010
Endothelin Receptor Antagonists in Diabetic Nephropathy
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease and affects an estimated 150 million people worldwide… 
2010
2010
Circulating tumor cell capture and analysis in a multicenter SWOG-coordinated prostate cancer trial.
TPS342 Background: Prostate cancer biomarkers are urgently needed to better inform treatment decisions. Recent studies have… 
2007
2007
Phase II ECOG trial of atrasentan in advanced renal cell carcinoma
5102 Background: Atrasentan, an oral selective endothelin A receptor antagonist, demonstrated activity in patients with RCC… 
2007
2007
Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK 2 activation
Banes-Berceli AK, Ketsawatsomkron P, Ogbi S, Patel B, Pollock DM, Marrero MB. Angiotensin II and endothelin-1 augment the… 
Review
2006
Review
2006
Targeting BoneMetastasis in Prostate Cancer with Endothelin ReceptorAntagonists
Recent advances in the understanding of prostate cancer biology and its progression to bone metastasis have led to the… 
2005
2005
Tumor-Secreted Autocrine Motility Factor (AMF): Causal Role in an Animal
Abstract : Cancer cachexia has three clinical features: I) loss of appetite (anorexia), 2) nutritional mal-absorption, and 3… 
2005
2005
Expediting Oncology Drug Approvals: The Public Backlash Against the FDA and Opportunities to Reform
The FDA has made great strides over the past twenty years in loosening drug approval regulations to speed important, life-saving… 
2005
2005
Atrasentan: A novel selective endothelin-A receptor antagonist
Accumulating data have demonstrated that the endothelin axis plays a role in the progression of many malignancies. Endothelin-1…